Longeveron (LGVN) EBT Margin Growth (1y) (2021 - 2026)
Longeveron (LGVN) EBT Margin Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1,526.00 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1,558.00 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -683.00 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 813.00 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 | 31,177.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31,177.00 |
| Dec 31, 2025 | -84,289.00 |
| Sep 30, 2025 | -577,690.00 |
| Jun 30, 2025 | -139,684.00 |
| Mar 31, 2025 | -91,776.00 |
| Dec 31, 2024 | 781,414.00 |
| Sep 30, 2024 | 295,960.00 |
| Jun 30, 2024 | 198,403.00 |
| Mar 31, 2024 | 1.45 Mn |
| Dec 31, 2023 | -436,264.00 |
| Sep 30, 2023 | 182,100.00 |
| Jun 30, 2023 | -168,550.00 |
| Mar 31, 2023 | -1.40 Mn |
| Dec 31, 2022 | -2.58 Mn |
| Sep 30, 2022 | 446,184.00 |
| Jun 30, 2022 | 304,622.00 |
| Mar 31, 2022 | 385,371.00 |
| Sep 30, 2021 | -982,078.00 |
| Jun 30, 2021 | -369,066.00 |
| Mar 31, 2021 | -516,189.00 |